Concepedia
Statistics
Publications
24
Citations
1.9K
H-Index
19
Active since
2010
Affiliations
Agios Pharmaceuticals (United States)(Current)
Memorial Sloan Kettering Cancer Center
The University of Texas MD Anderson Cancer Center
Institut Gustave Roussy
Massachusetts General Hospital
Samuel Agresta is an author at Agios Pharmaceuticals (United States) specializing in medicine, pharmacology, and oncology.
Publications per year
2010–2025
Ivosidenib induces deep durable remissions in patients with newly diagnosed IDH1-mutant acute myeloid leukemia
Gail J. Roboz, Courtney D. DiNardo, Eytan M. Stein et al. · Blood · 2019 · 375 citations · Full text
Medicine, Hematology, Pharmacology +12
Enasidenib, an inhibitor of mutant IDH2 proteins, induces durable remissions in older patients with newly diagnosed acute myeloid leukemia
Daniel A. Pollyea, Martin S. Tallman, Stéphane de Botton et al. · Leukemia · 2019 · 250 citations · Full text
Medicine, Oncology, Pharmacology +14
Safety and activity of ivosidenib in patients with IDH1-mutant advanced cholangiocarcinoma: a phase 1 study
Maeve A. Lowery, Howard A. Burris, Filip Jankú et al. · The Lancet. Gastroenterology & hepatology · 2019 · 219 citations · Full text
Medicine, Oncology, Pharmacology +10
Serum 2-hydroxyglutarate levels predict isocitrate dehydrogenase mutations and clinical outcome in acute myeloid leukemia
Courtney D. DiNardo, Kathleen J. Propert, Alison W. Loren et al. · Blood · 2013 · 200 citations · Full text
Medicine, Hematology, Molecular Genetics +9
Prospective serial evaluation of 2-hydroxyglutarate, during treatment of newly diagnosed acute myeloid leukemia, to assess disease activity and therapeutic response
Amir Fathi, Hossein Sadrzadeh, Darrell R. Borger et al. · Blood · 2012 · 122 citations · Full text
Medicine, Hematology, Oncology +10
1–5 of 24